Teva Pharma Is ‘Ideal Partner,’ Mesoblast CEO Itescu Says
Teva Pharmaceutical Industries Ltd. (TEVA) is an “even more of an ideal partner” than Cephalon Inc. (CEPH) to develop stem cell-based treatments, Mesoblast Ltd. (MSB) Chief Executive Officer Silviu Itescu said.
Teva, the world’s largest generic-drug maker, agreed yesterday to buy Cephalon for $6.8 billion, trumping a hostile offer from Valeant Pharmaceuticals International Inc. (VRX) Cephalon owns 19.99 percent of Melbourne-based Mesoblast.
Teva is “a much larger specialty pharmaceutical company looking to build themselves into a biologics leader,” Itescu said in a telephone interview today.
To contact the editor responsible for this story: Jason Gale at firstname.lastname@example.org